Table 1.
Baseline characteristics of the guselkumab group (n = 12) and the adalimumab group (n = 13)
| Guselkumab group (N=12) | Adalimumab group (N=13) | P value | |
|---|---|---|---|
| Age | 53.5 (46.0, 61.8) | 55.0 (48.5, 58.0) | 1.0000 |
| Male/female | 1/11 | 3/10 | 0.5930 |
| Disease duration (months) | 29.0 (6.3, 73.8) | 18.0 (6.5, 324) | 0.4459 |
| Age at diagnosis | 50.5 (41.5, 56.8) | 45.0 (31.5, 55.5) | 0.2530 |
| Peripheral joint, n (%) | 12 (100) | 13 (100) | |
| Sternoclavicular joint, n (%) | 7/12 (58.3) | 10/13 (76.9) | 0.4110 |
| Sacroiliac joint, n (%) | 7/12 (58.3) | 7/13 (53.9) | 1.0000 |
| Spine, n (%) | 2/12 (16.7) | 3/13 (23.1) | 1.0000 |
| Concomitant CS, n (%) | 0 (0) | 2 (16.7) | 0.4857 |
| History of csDMARDs | MTX 5, SASP 2 | MTX 11, SASP 2, CyA 1 | 0.0730 |
| History of TNFi, n (%) | 4 (33.3) | 2 (15.4) | 0.1602 |
| History of IL-17i, n (%) | 1 (8.3) | 0 (0) | 0.4800 |
| Weight (kg) | 54.9 (48.3, 68.2) | 56.1 (51.5, 72.8) | 0.5496 |
| BMI | 21.7 (19.4, 27.7) | 23.0 (20.5, 26.3) | 0.4792 |
| Smoking history, n (%) | 8 (66.7) | 9 (69.2) | 1.0000 |
| PPPASI | 7.2 (1.7, 14.6) | 3.0 (1.4, 18.6) | 0.5137 |
| Patient pain VAS (cm) | 5.3 (3.0, 7.5) | 4.5 (2.3, 6.6) | 0.4138 |
| Patient global VAS (cm) | 5.3 (3.4, 7.5) | 4.0 (3.5, 6.2) | 0.3685 |
| SJ66 | 1.5 (0, 3.0) | 1.0 (0, 1.5) | 0.3973 |
| TJ68 | 4.0 (3.0, 7.3) | 8.0 (3.5, 13.5) | 0.1633 |
| DAPSA | 17.3 (10.3, 34.0) | 19.7 (15.0, 26.8) | 0.7223 |
| HAQ | 0.69 (0.28, 1.34) | 0.75 (0.19, 1.50) | 0.8911 |
| EQ-5D | 0.61 (0.54, 0.77) | 0.61 (0.52, 0.73) | 0.9738 |
| CRP | 0.13 (0.07, 0.65) | 0.46 (0.05, 1.00) | 0.8275 |
| ESR | 22.5 (9.0, 48.5) | 19.0 (12.0, 25.0) | 0.5853 |
Data are shown by median (quartile) or n (%). p values were determined by Fisher’s exact test or the Wilcoxon rank sum test
CS corticosteroid, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, TNFi tumor necrosis factor inhibitor, IL-17i interleukin 17 inhibitor, BMI body mass index, PPPASI Palmoplantar Pustulosis Area and Severity Index, VAS visual analog scale, SJ swollen joint, TJ tender Joint, DAPSA disease activity in psoriatic arthritis, HAQ Health Assessment Questionnaire, EQ-5D EuroQOL score with 5 dimensions, CRP C-reactive protein, ESR erythrocyte sedimentation rate
*p<0.05: guselkumab group (n=12) vs adalimumab group (n=13)